Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine): Withdrawals due to adverse events
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Oral 5‐aminosalicylic acid vs comparator 5‐aminosalicylic acid formulation Withdrawal due to adverse events · people with quiescent UC It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty). Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane Headline outcomes only | RR 1.25 | 5 studies · 457 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.